Amarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations

Dow Jones

01/09

By Elias Schisgall

Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026.

Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year.

Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million.

Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 08, 2026 11:24 ET (16:24 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2602396401"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602396401\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602396401?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 00:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602396401","market":"us","top_or_hot":-1,"title":"Amarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026. \n</p>\n<p>\n  Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year. \n</p>\n<p>\n  Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million. \n</p>\n<p>\n  Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 11:24 ET (16:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-09 00:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026. \n</p>\n<p>\n  Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year. \n</p>\n<p>\n  Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million. \n</p>\n<p>\n  Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 11:24 ET (16:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602396401","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602396401","pubTimestamp":1767889440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026.Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year.Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million.Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AMRN":"阿玛琳"},"translate_title":"Amarin股价因现金流超出预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRN":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026. \n\n\n  Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year. \n\n\n  Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million. \n\n\n  Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 11:24 ET (16:24 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}